![]() The median times to neutrophil recovery (P =. 007) and there was no difference in the risk of relapse or progression (P =. However, the cumulative incidence of overall cGVHD was lower with G-BM (HR. With a median follow-up of 36 months (range, 9.6 to 48), comparing G-BM with G-PB, there was no difference between the 2 arms with respect to the primary outcome of this study (hazard ratio. The primary endpoint was time to treatment failure, defined as a composite of extensive cGVHD, relapse/disease progression, and death. We conducted a phase 3, open-label, multicenter randomized trial of 230 adults with hematologic malignancies receiving allografts from siblings after myeloablative conditioning to compare G-PB with G-BM. A potential alternative allograft is filgrastim-stimulated marrow (G-BM), which we hypothesized may be associated with prompt hematopoietic recovery but with less cGVHD. Although the use of G-PB results in faster hematopoietic recovery, it is also associated with more chronic graft-versus-host disease (cGVHD). In adult hematopoietic cell transplantation (HCT), filgrastim-mobilized peripheral blood (G-PB) has largely replaced unstimulated marrow for allografting. 16 Department of Medicine, University of Colorado, Denver, Colorado.15 Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.14 Department of Oncology, Hôpital Hotel-Dieu, Quebec City, Quebec, Canada.13 Department of Medicine, London Health Sciences Center and University of Western Ontario, London, Ontario, Canada.12 Department of Medicine, Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.11 Department of Hematology, Royal Adelaide Hospital, Adelaide, Australia.10 Hematology Department, Auckland City and Starship Children's Hospitals, Auckland, New Zealand.9 Clinical Haematology and BMT Service, Royal Melbourne Hospital, Melbourne, Australia.8 Department of Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington.7 Departments of Oncology and Biostatistics, Princess Margaret Cancer Center and University of Toronto, Toronto, Ontario, Canada.6 Department of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, Manitoba, Canada.5 Department of Medicine, Leukemia/Bone Marrow Transplant Program, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada.4 Department of Medicine, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.3 Hematology-Oncology, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada. ![]() Electronic address: 2 Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |